Pyxis Oncology Inc [PYXS] stock is trading at $1.56, up 1.96%. An important factor to consider is whether the stock is rising or falling in short-term value. The PYXS shares have gain 8.33% over the last week, with a monthly amount glided 2.63%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Pyxis Oncology Inc [NASDAQ: PYXS] stock has seen the most recent analyst activity on November 21, 2024, when William Blair downgraded its rating to a Mkt Perform. Previously, Stephens started tracking the stock with Overweight rating on November 08, 2024, and set its price target to $13. On August 08, 2024, Stifel initiated with a Buy rating and assigned a price target of $10 on the stock. BTIG Research initiated its recommendation with a Buy and recommended $8 as its price target on February 09, 2024. Leerink Partners started tracking with a Outperform rating for this stock on January 23, 2024, and assigned it a price target of $12. In a note dated September 05, 2023, RBC Capital Mkts initiated an Outperform rating and provided a target price of $7 on this stock.
Pyxis Oncology Inc [PYXS] stock has fluctuated between $1.39 and $6.85 over the past year. Currently, Wall Street analysts expect the stock to reach $8.5 within the next 12 months. Pyxis Oncology Inc [NASDAQ: PYXS] shares were valued at $1.56 at the most recent close of the market. An investor can expect a potential return of 444.87% based on the average PYXS price forecast.
Analyzing the PYXS fundamentals
Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -3.43%, Pretax Profit Margin comes in at -2.93%, and Net Profit Margin reading is -2.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.36 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5150 points at the first support level, and at 1.4700 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6000, and for the 2nd resistance point, it is at 1.6400.
Ratios To Look Out For
For context, Pyxis Oncology Inc’s Current Ratio is 7.33. On the other hand, the Quick Ratio is 7.33, and the Cash Ratio is 0.59. Considering the valuation of this stock, the price to sales ratio is 5.74, the price to book ratio is 0.60.
Transactions by insiders
Recent insider trading involved Connealy Pamela Ann, CFO & COO, that happened on Nov 26 ’24 when 88850.0 shares were purchased.
